Prion Protein (PRNP)

<table class=“infobox infobox-protein”> <tr> <th class=“infobox-header” colspan=“2”>Cellular Prion Protein (PrP)</th> </tr> <tr> <td class=“label”>Gene</td> <td>PRNP</td> </tr> <tr> <td class=“label”>UniProt</td> <td><a href=“https://www.uniprot.org/uniprot/P04156” target=“_blank”>P04156</a></td> </tr> <tr> <td class=“label”>Molecular Weight</td> <td>33-35 kDa (253 amino acids)</td> </tr> <tr> <td class=“label”>Localization</td> <td>Cell membrane ( GPI-anchored), cytoplasm, nucleus</td> </tr> <tr> <td class=“label”>Family</td> <td>Prion protein family</td> </tr> <tr> <td class=“label”>Chromosome</td> <td>20p13</td> </tr> <tr> <td class=“label”>Diseases</td> <td>Creutzfeldt-Jakob Disease, Fatal Familial Insomnia, Kuru, Bovine Spongiform Encephalopathy</td> </tr> <tr> <td class=“label”>KG Connections</td> <td><a href=“/atlas” style=“color:#4fc3f7”>1 edges</a></td> </tr> </table>

Cellular Prion Protein (PRNP)

Pathway / Mechanism Diagram

flowchart TD
    A["Gene<br/>Expression"] --> B["Prion  (PRNP)<br/>Protein"]
    B --> C["Protein<br/>Folding and Structure"]
    C --> D["Biological<br/>Activity"]
    D --> E["Cellular<br/>Function"]
    F["Regulation/<br/>Modification"] --> D
    E --> G["Normal<br/>Physiology"]
    B -->|"mutation"| H["Pathological<br/>State"]
    H --> I["Disease<br/>Phenotype"]

Introduction

The cellular prion protein (PrP), encoded by the PRNP gene, is a GPI-anchored glycoprotein expressed predominantly in the central nervous system. While its precise physiological function remains incompletely understood, PrP is best known for its central role in prion diseases—a unique class of fatal neurodegenerative disorders caused by the pathological conversion of the normal cellular isoform (PrP^C) into an infectious, self-propagating isoform (PrP^Sc) [@Linden2024][@Watzlawik2023].

Prion diseases include Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), kuru, and variant CJD linked to bovine spongiform encephalopathy (BSE). These disorders represent a paradigm in neurodegeneration where a single protein can undergo a conformational transformation that triggers progressive neurotoxicity and spongiform changes in the brain. The discovery that prion diseases can be infectious, inherited, and sporadic has fundamentally transformed our understanding of protein misfolding in neurodegeneration [@Prusiner2015][@Caughey2023].

Beyond its role in prion diseases, PrP has been implicated in other neurodegenerative conditions, including Alzheimer’s disease, where interactions between PrP and amyloid-beta may influence disease pathogenesis [@Watts2014].

Structure and Biochemistry

Protein Architecture

PrP is a 253-amino acid protein with a distinctive domain structure [@Watzlawik2023][@Zanusso2016]:

N-terminal signal peptide (1-23 aa): Directs translocation to the endoplasmic reticulum
Flexible N-terminal domain (23-125 aa): Contains five octapeptide repeats that coordinate copper ions (Cu²⁺)
Structured C-terminal domain (126-231 aa): Three α-helices and two β-strands forming a globular fold
GPI anchor signal (232-253 aa): Directs addition of the glycosylphosphatidylinositol anchor for membrane attachment

Conformational States

The key property of PrP is its ability to adopt distinct conformational states:

PrP^C (cellular): Predominantly α-helical, soluble, protease-sensitive, and non-infectious
PrP^Sc (scrapie): Enriched in β-sheet structure, insoluble, partially protease-resistant, and capable of self-propagation
PrP^C can be converted to PrP^Sc through interaction with existing PrP^Sc seeds, a process central to prion disease pathogenesis

The structural transition from α-helix to β-sheet is the molecular basis of prion propagation and the formation of amyloid fibrils that accumulate in the brain [@Caughey2014][@Soto2011].

Post-Translational Modifications

PrP undergoes several important modifications:

N-linked glycosylation at Asn181 and Asn197: Affects folding, trafficking, and disease susceptibility
Disulfide bond between Cys179 and Cys214: Stabilizes the C-terminal globular domain
GPI anchoring: Targets PrP to lipid rafts in the plasma membrane
Copper binding: The octapeptide repeats can coordinate Cu²⁺ ions with varying affinity

Normal Physiological Function

Despite extensive research, the physiological functions of PrP remain incompletely defined. Several lines of evidence support important roles in:

Synaptic Function

PrP is highly expressed at synapses, particularly in the hippocampus and cerebellum. Studies suggest it participates in [@Purro2012][@Bellinger2015]:

Synaptic plasticity and long-term potentiation
Synaptic vesicle trafficking and neurotransmitter release
Maintenance of synaptic structure

Copper Homeostasis

The octapeptide repeat region binds copper ions with high affinity, suggesting a role in:

Cellular copper uptake and distribution
Antioxidant defense through copper-dependent enzymes
Modulation of synaptic copper signaling

Cell Signaling

PrP interacts with multiple cell surface proteins and can:

Activate signaling cascades through various receptors
Interact with neural cell adhesion molecules
Modulate neuroprotective pathways

Neuroprotection

PrP may provide neuroprotective effects through:

Anti-apoptotic signaling
Protection against oxidative stress
Regulation of autophagy

Prion Diseases

Disease Spectrum

Prion diseases can be acquired through infection, inherited through mutations in PRNP, or arise sporadically [@Belay1999][@Geschwind2015]:

Sporadic Creutzfeldt-Jakob Disease (sCJD): Most common form (~85% of cases), unknown etiology
Inherited Prion Diseases: Caused by PRNP mutations (e.g., P102L, D178N, E200K) that predispose to spontaneous conversion
Variant CJD (vCJD): Acquired from BSE-contaminated food products
Kuru: Acquired through ritualistic cannibalism
Fatal Familial Insomnia (FFI): Characterized by progressive insomnia and autonomic dysfunction

Pathogenesis

PrP^Sc accumulation in the brain leads to:

Spongiform degeneration: Vacuolation of brain tissue
Neuronal loss: Progressive death of neurons
Gliosis: Activation of astrocytes and microglia
Amyloid plaque formation: In some variants

The neurotoxicity of PrP^Sc appears to involve disruption of synaptic function, induction of endoplasmic reticulum stress, and activation of apoptotic pathways [@Colby2010][@Caughey2009].

Genetic Susceptibility

Polymorphisms at codon 129 of PRNP (methionine or valine) strongly influence disease susceptibility and phenotype:

129M/M: Predisposes to vCJD and certain CJD subtypes
129V/V: Associated with longer incubation times
Heterozygosity may provide some protection

Relationship to Alzheimer’s Disease

Interesting connections between PrP and AD have emerged [@Watts2014]:

PrP as an Aβ Receptor

PrP can bind amyloid-beta peptides and may function as a receptor mediating Aβ-induced synaptic dysfunction. This interaction may:

Facilitate Aβ toxicity at synapses
Activate downstream signaling pathways
Contribute to early synaptic impairment in AD

Shared Mechanisms

Both prion diseases and AD involve:

Protein misfolding and aggregation
Synaptic loss
Progressive neurodegeneration
spreading through brain networks

Therapeutic Implications

Understanding the intersection of PrP and AD pathology may reveal novel therapeutic targets for both conditions.

Molecular Mechanisms of PrP-Aβ Interaction

Binding Sites:

The Aβ binding region on PrP is located in the N-terminal domain
Specific amino acids (including glutamine and asparagine residues) facilitate Aβ binding
The interaction is thought to be largely hydrophobic with some electrostatic components

Downstream Signaling:

PrP-Aβ binding activates Fyn kinase
Leads to NMDA receptor phosphorylation
Results in excitotoxic calcium influx
Triggers downstream apoptotic pathways

Synaptic Effects:

PrP mediates Aβ-induced synaptic spine loss
Impairs long-term potentiation (LTP)
Disrupts synaptic plasticity mechanisms
Contributes to early cognitive deficits

PrP in Other Neurodegenerative Diseases

Parkinson’s Disease:

PrP may interact with alpha-synuclein
Potential role in Lewy body formation
Possible influence on dopaminergic neuron survival

Huntington’s Disease:

PrP expression altered in HD models
May interact with mutant huntingtin
Potential contribution to synaptic dysfunction

Amyotrophic Lateral Sclerosis:

PrP implicated in TDP-43 proteinopathy
Potential role in motor neuron vulnerability
May influence disease progression

PrP and Neuroinflammation

Microglial Activation:

PrP can be released from neurons in exosomes
Extracellular PrP may activate microglia
Contributes to chronic neuroinflammation
Creates feedback loop promoting neurodegeneration

Cytokine Regulation:

PrP influences cytokine production
Modulates inflammatory responses
May both promote and suppress inflammation depending on context

Blood-Brain Barrier:

PrP affects BBB integrity
Dysregulation may allow peripheral immune cell entry
Contributes to neuroinflammatory processes

Cellular PrP Functions

Protein Quality Control:

PrP interacts with cellular quality control machinery
May help target misfolded proteins for degradation
Loss of PrP function may impair protein clearance

Metal Ion Homeostasis:

Copper binding is well-characterized
PrP may also bind other metal ions (zinc, iron)
Metal dyshomeostasis is implicated in multiple neurodegenerative diseases

Cell Adhesion:

PrP functions as a cell adhesion molecule
Mediates cell-cell interactions at synapses
Influences neuronal connectivity during development

PrP in Aging and Cellular Senescence

Age-Related Changes:

PrP expression changes with age
Oxidative modifications accumulate
May contribute to age-related neuronal vulnerability

Cellular Senescence:

PrP may influence cellular senescence pathways
Senescent neurons show altered PrP expression
Could contribute to age-related neurodegeneration

PrP Spread and Propagation

Prion-Like Mechanisms:

Aβ and tau can propagate via prion-like mechanisms
PrP may facilitate this spread
Template-driven misfolding in other proteins

Tissue-Specific Vulnerability:

Neurons with high PrP expression are more vulnerable
Different brain regions show varying susceptibility
Regional PrP levels influence disease patterns

Biomarkers and Diagnostic Applications

Fluid Biomarkers:

CSF PrP levels as potential biomarker
14-3-3 protein in CSF for CJD diagnosis
Tau and neurofilament light chain measurements

Imaging Biomarkers:

PET ligands for PrP aggregates
MRI for detecting spongiform changes
Diffusion tensor imaging for connectivity changes

Genetic Markers:

PRNP polymorphisms modify disease risk
Codon 129 influences sporadic CJD
Octapeptide repeat number variations

Therapeutic Strategies

Current Approaches

No effective disease-modifying therapies exist for prion diseases. Strategies under investigation include [@Aguib2022][@Johnson2005][@Caughey2009]:

Anti-prion compounds: Small molecules that stabilize PrP^C or inhibit PrP^Sc formation
Immunotherapy: Antibodies targeting PrP^Sc or preventing conversion
Gene silencing: siRNA or antisense oligonucleotides to reduce PrP expression
Symptomatic treatment: Managing cognitive and behavioral symptoms

Challenges

The blood-brain barrier limits drug delivery
PrP^Sc exists in multiple strains with distinct properties
Intervention must occur early in disease course
Need for reliable biomarkers to guide treatment
Heterogeneity of clinical presentations complicates diagnosis

Specific Prion Disease Types

Sporadic Creutzfeldt-Jakob Disease (sCJD)

sCJD represents approximately 85% of all human prion disease cases:

Epidemiology

Incidence: 1-2 per million annually worldwide
Typically presents in individuals 50-70 years of age
Slight male predominance in some populations

Clinical Features

Rapidly progressive dementia
Ataxia and cerebellar signs
Myoclonus (especially startle-induced)
Visual disturbances including cortical blindness
Pyramidal and extrapyramidal signs
Akinetic mutism in late stages

Subtypes

MM1/MV1: Most common, rapid progression
VV2: Cerebellar predominant, slower progression
MM2: Longer disease duration

Diagnostic Features

14-3-3 protein in cerebrospinal fluid
Periodic sharp wave complexes on EEG
MRI hyperintensities in cortex and basal ganglia
Real-time quaking-induced conversion (RT-QuIC) positive

Variant Creutzfeldt-Jakob Disease (vCJD)

vCJD results from exposure to bovine spongiform encephalopathy (BSE):

Epidemiology

Linked to consumption of BSE-contaminated beef
First described in 1996 in the United Kingdom
Approximately 230 cases worldwide

Clinical Features

Psychiatric symptoms at onset (depression, anxiety)
Behavioral changes and personality alterations
Sensory abnormalities including dysesthesia
Ataxia developing later in disease course
Progressive dementia
Longer survival than sCJD (median 14-18 months)

Pathological Features

PrP amyloid plaques (florid plaques) throughout brain
PrP deposition in lymphoid tissues
Spongiform changes in basal ganglia and cerebellum

Fatal Familial Insomnia (FFI)

FFI represents a unique prion disease with predominant sleep dysfunction:

Genetic Basis

Caused by PRNP mutation D178N with methionine at codon 129
Autosomal dominant inheritance
Incomplete penetrance depending on codon 129 genotype

Clinical Features

Progressive insomnia
Autonomic dysfunction (hyperhidrosis, hypertension)
Dysphagia and weight loss
Cognitive decline in later stages
Visual and auditory hallucinations

Neuropathology

Selective thalamic degeneration, especially dorsomedial nucleus
Minimal spongiform change
PrP deposition in thalamus and inferior olive

Gerstmann-Sträussler-Scheinker Syndrome (GSS)

GSS is a rare inherited prion disease:

Genetic Basis

PRNP mutations including P102L, A117V, F198I, Q217R
Autosomal dominant inheritance
Variable age of onset (35-55 years typically)

Clinical Features

Progressive ataxia
Dementia (later onset than ataxia)
Pyramidal signs
Extrapyramidal features in some subtypes
Disease duration: 2-10 years

Pathological Features

PrP amyloid plaques throughout cerebellum and cerebral cortex
Multicentric plaque formation
Spongiform changes variable

Iatrogenic Prion Disease

Transmission through medical procedures includes:

Sources of Transmission

Dura mater grafts (historical)
Corneal transplants
Human growth hormone (historical)
Gonadotropin hormone
Blood transfusion (rare cases)

Clinical Features

Similar to sCJD but longer incubation periods
For growth hormone cases: 5-20 year incubation
Typically rapid progression once symptomatic

Cellular and Molecular Mechanisms

PrP^Sc Conversion Mechanism

The conversion of PrP^C to PrP^Sc involves:

Template-Directed Conversion

PrP^Sc serves as template for conversion of PrP^C
Conformational information transfer through direct interaction
Heterodimer formation as intermediate

Nucleation-Dependent Polymerization

PrP^Sc aggregates form through seeded polymerization
Lag phase followed by exponential growth
Fibril elongation through addition of monomers

Structural Transition

Loss of α-helical content (from 40% to 20%)
Increase in β-sheet structure (from 10% to 40%)
Domain rearrangement in C-terminal region

PrP^Sc Strain Diversity

Prion strains represent different conformations:

Strain Characteristics

Distinct physicochemical properties
Different incubation periods in hosts
Variable neuropathology
Differential protease resistance patterns

Mechanisms of Strain Variation

Different folding patterns of PrP^Sc
Variations in aggregation state
Distinct protofibril structures

Cellular Toxicity Pathways

PrP^Sc causes neurotoxicity through multiple mechanisms:

ER Stress

Accumulation of misfolded proteins triggers unfolded protein response
CHOP-mediated apoptosis
Disruption of calcium homeostasis

Oxidative Stress

Mitochondrial dysfunction
Increased reactive oxygen species
Lipid peroxidation
DNA damage

Synaptic Dysfunction

Loss of synaptic proteins
Impaired neurotransmitter release
Disruption of synaptic plasticity
Calcium dysregulation

Glial Activation

Microglial activation and inflammation
Astrocyte reactivity
Cytokine release
Neuroinflammation amplification

PrP and Other Neurodegenerative Diseases

PrP in Parkinson’s Disease

Connections between PrP and PD include:

PrP expression in dopaminergic neurons
Potential interaction with α-synuclein
Role in metal homeostasis relevant to PD
Possible common pathways in protein aggregation

PrP and Amyotrophic Lateral Sclerosis

ALS shares features with prion diseases:

PrP deposition in some ALS cases
Common mechanisms of protein aggregation
Overlapping pathways of cellular stress

Metal Ion Homeostasis

PrP interacts with various metal ions:

Copper

High affinity binding to octapeptide repeats
Role in copper uptake and distribution
Antioxidant function through SOD-like activity
Dyshomeostasis in prion disease

Iron

PrP affects iron metabolism
Iron dysregulation in prion disease
Possible role in oxidative stress

Zinc

PrP-zinc interactions
Potential signaling functions

PrP as a Therapeutic Target

Immunotherapeutic Approaches

Active Immunization

Vaccines targeting PrP^Sc
Generation of anti-PrP antibodies
Challenges: overcoming immune tolerance
Clinical trials in animal models

Passive Immunization

Administration of anti-PrP monoclonal antibodies
Examples: 6D11, 8H4, Prioclone
Delivery challenges across blood-brain barrier

Small Molecule Inhibitors

Polyanionic Compounds

Sulfated glycans inhibit PrP conversion
Pentosan polysulfate in clinical use
Limitations: poor BBB penetration

Tetracycline Derivatives

Doxycycline shows anti-prion activity
Binding to PrP^Sc prevents aggregation
Clinical trials ongoing

Metal Chelators

Cu/Zn chelation reduces conversion
Clioquinol trials in prion disease

Gene Silencing Approaches

Antisense Oligonucleotides

Target PRNP mRNA
Reduce PrP^C expression
ASO trials in development
Advantages: specificity, distribution

RNAi Approaches

siRNA targeting PRNP
Viral vector delivery
Challenges: efficient CNS delivery

Protein-Based Therapies

Dominant-Negative PrP

Expression of mutant PrP that interferes with conversion
Competitive inhibition of PrP^Sc formation
Proof-of-concept in cell models

Chaperone-Based Approaches

Heat shock proteins in PrP metabolism
Enhancement of PrP^C folding
Targeting protein quality control

Diagnostic Biomarkers

Current Biomarkers

Cerebrospinal Fluid Markers

14-3-3 protein: sensitivity ~95%, specificity ~40%
Tau protein: elevated in some cases
Neurofilament light chain: promising marker

Real-Time Quaking-Induced Conversion (RT-QuIC)

Sensitivity: 80-90% for sCJD
Specificity: >95%
Detects PrP^Sc seeding activity
Applied to CSF, olfactory epithelium, skin

Emerging Biomarkers

Blood-Based Markers

PrP detection in plasma
Exosome-associated PrP^Sc
Sensitive detection methods in development

Imaging Biomarkers

PET ligands for PrP^Sc
MRI advanced techniques
Diffusion tensor imaging

Brain Atlas Resources

Allen Human Brain Atlas: PRNP expression search
Allen Mouse Brain Atlas: Prnp search
BrainSpan Developmental Transcriptome: PRNP developmental expression

Clinical Trials and Emerging Therapies

Anti-Prion Compounds in Development:

Polyanionic compounds that stabilize PrP^C
Small molecules targeting PrP^Sc formation
Natural products with anti-prion activity

Immunotherapy Approaches:

Active immunization with PrP antigens
Passive monoclonal antibody administration
Antibody fragments for better brain penetration
CAR-T cell approaches for prion clearance

Gene Therapy Strategies:

PRNP knockdown using RNAi approaches
CRISPR-based gene editing for correction
PRNP expression modulation
Viral vector-mediated delivery of anti-prion constructs

Combination Therapies:

Antibody plus small molecule combinations
Gene therapy with pharmacological adjuncts
Multi-target approaches for maximum effect

Protein Dynamics and Misfolding

Folding Pathways:

PrP folding occurs in the endoplasmic reticulum
Misfolding can occur at multiple stages
Quality control mechanisms normally prevent accumulation
Failure of quality control leads to disease

Aggregation Mechanisms:

Nucleation-dependent polymerization
Formation of oligomeric intermediates
Amyloid fibril assembly
Strain variation through different conformations

Cellular Quality Control:

ER-associated degradation (ERAD)
Autophagy-lysosome pathway
Proteasome-mediated degradation
Unfolded protein response activation

PrP in Prion Disease Subtypes

Sporadic CJD (sCJD):

Most common form (~85% of cases)
No known genetic or infectious cause
Likely spontaneous PrP^Sc formation
Variable clinical presentation based on PRNP genotype

Variant CJD (vCJD):

Acquired from BSE exposure
Younger age of onset than sCJD
Prominent psychiatric features
Long incubation period

Iatrogenic CJD:

Transmission through medical procedures
corneal transplants, dura mater grafts
Contaminated human growth hormone
Blood transfusion transmission documented

Fatal Familial Insomnia (FFI):

PRNP D178N mutation with methionine at codon 129
Primary insomnia with autonomic dysfunction
Selective thalamic degeneration
Distinct clinical phenotype from CJD

PrP Structural Biology

X-ray Crystallography:

Detailed structure of C-terminal domain
Insight into helix-turn-helix arrangement
Domain organization in the structured region

NMR Studies:

Dynamics of N-terminal domain
Flexible regions in physiological conditions
Conformational changes upon misfolding

Cryo-EM:

Amyloid fibril structures
Different prion strain conformations
Polymorphic fibril architectures

PrP in Neurodevelopment

Developmental Expression:

High expression during embryogenesis
Peak levels in early postnatal period
Sustained expression in adult brain
Cell type-specific patterns

Developmental Functions:

Neuronal differentiation
Synapse formation
Myelination
Astrocyte maturation

Knockout Phenotypes:

Relatively mild phenotype in Prnp-/- mice
Compensatory mechanisms exist
Subtle neurological deficits in specific contexts

Research Methods

Biochemical Approaches:

Western blotting for PrP detection
ELISA for quantification
Pulse-chase experiments for trafficking
Proteomics for interaction mapping

Cell Biology:

Cell culture models (neurons, astrocytes)
Primary neuronal cultures
Stem cell-derived neurons
Live cell imaging

Animal Models:

Mouse models of prion disease
Transgenic mice expressing mutant PRNP
Knock-in models with human PRNP
Zebrafish models for development

Structural Methods:

X-ray crystallography
NMR spectroscopy
Cryo-electron microscopy
Mass spectrometry

External Links

UniProt: P04156 - PRNP
AlphaFold: PrP Structure Prediction
OMIM: 176640 - PRNP
GeneCards: PRNP
PubMed: Prion protein literature
Human Protein Atlas: PRNP expression
STRING Database: PrP interaction network

Prion Disease Surveillance and Public Health

Global Surveillance Networks:

National CJD surveillance systems
WHO collaborative surveillance
Rapid alert systems for new variants

BSE and Food Safety:

Cattle testing protocols
Feed restrictions and controls
Human exposure risk assessment

Infection Control:

Sterilization protocols for surgical equipment
Blood donor screening
Tissue transplantation safety

PrP and Copper Metabolism Connection

Copper Binding Properties:

High affinity binding to octapeptide repeats
Different affinity for Cu(I) and Cu(II)
Multiple binding sites per PrP molecule

Copper Transport:

PrP may function as copper receptor
Facilitates copper uptake into cells
Participates in cellular copper distribution

Implications for Disease:

Copper dyshomeostasis in prion disease
Potential therapeutic targeting of copper pathways
Interaction with other neurodegenerative processes

PrP and Zinc Metabolism

Zinc Binding:

PrP can bind zinc ions
Different binding site than copper
Modulates PrP aggregation properties

Zinc Signaling:

Important for synaptic function
PrP may regulate zinc availability
Implications for synaptic plasticity

PrP in Oligodendrocyte Function

Myelin Maintenance:

PrP expressed in oligodendrocytes
Important for myelin integrity
Dysfunction may contribute to demyelination

White Matter Pathology:

White matter changes in CJD
Potential for therapeutic intervention
Imaging biomarkers for progression

PrP in Astrocyte Function

Astrocyte Expression:

PrP expressed in astrocytes
Functions in astrocyte-neuron communication
May influence neurovascular unit

Reactive Astrocytosis:

Astrocyte activation in prion disease
Both protective and harmful roles
Potential therapeutic target

PrP and Blood-Brain Barrier

BBB Regulation:

PrP influences BBB development
Maintains BBB integrity
Dysfunction allows peripheral access

Therapeutic Implications:

Drug delivery challenges
Strategies to improve brain penetration
Engineering of therapeutic antibodies

Genetic Epidemiology

Population Studies:

Allele frequency variations
Founder mutations in specific populations
Consanguinity effects on incidence

Genotype-Phenotype Correlations:

129 polymorphism effects
Mutation-specific clinical presentations
Modifier genes and modifiers

PrP in Veterinary Medicine

Animal Prion Diseases:

Scrapie in sheep and goats
BSE in cattle
Chronic wasting disease in cervids
Feline spongiform encephalopathy

Zoonotic Potential:

Species barrier studies
Cross-species transmission
Public health implications

Future Research Directions

Basic Science Priorities:

Structural basis for strain variation
Molecular mechanisms of neurotoxicity
Early diagnostic markers

Clinical Priorities:

Disease-modifying therapies
Biomarkers for clinical trials
Early intervention strategies

Therapeutic Priorities:

Small molecule development
Antibody therapeutics
Gene therapy approaches
Combination therapies

Prion Protein (PRNP)

Cellular Prion Protein (PRNP)

Pathway / Mechanism Diagram

Introduction

Structure and Biochemistry

Protein Architecture

Conformational States

Post-Translational Modifications

Normal Physiological Function

Synaptic Function

Copper Homeostasis

Cell Signaling

Neuroprotection

Prion Diseases

Disease Spectrum

Pathogenesis

Genetic Susceptibility

Relationship to Alzheimer’s Disease

PrP as an Aβ Receptor

Shared Mechanisms

Therapeutic Implications

Molecular Mechanisms of PrP-Aβ Interaction

PrP in Other Neurodegenerative Diseases

PrP and Neuroinflammation

Cellular PrP Functions

PrP in Aging and Cellular Senescence

PrP Spread and Propagation

Biomarkers and Diagnostic Applications

Therapeutic Strategies

Current Approaches

Challenges

Specific Prion Disease Types

Sporadic Creutzfeldt-Jakob Disease (sCJD)

Variant Creutzfeldt-Jakob Disease (vCJD)

Fatal Familial Insomnia (FFI)

Gerstmann-Sträussler-Scheinker Syndrome (GSS)

Iatrogenic Prion Disease

Cellular and Molecular Mechanisms

PrP^Sc Conversion Mechanism

PrP^Sc Strain Diversity

Cellular Toxicity Pathways

PrP and Other Neurodegenerative Diseases

PrP in Parkinson’s Disease

PrP and Amyotrophic Lateral Sclerosis

Metal Ion Homeostasis

PrP as a Therapeutic Target

Immunotherapeutic Approaches

Small Molecule Inhibitors

Gene Silencing Approaches

Protein-Based Therapies

Diagnostic Biomarkers

Current Biomarkers

Emerging Biomarkers

Brain Atlas Resources

Clinical Trials and Emerging Therapies

Protein Dynamics and Misfolding

PrP in Prion Disease Subtypes

PrP Structural Biology

PrP in Neurodevelopment

Research Methods

See Also

External Links

Prion Disease Surveillance and Public Health

PrP and Copper Metabolism Connection

PrP and Zinc Metabolism

PrP in Oligodendrocyte Function

PrP in Astrocyte Function

PrP and Blood-Brain Barrier

Genetic Epidemiology

PrP in Veterinary Medicine

Future Research Directions

References